POLYCYTHEMIA VERA, POST-POLYCYTHEMIC MYELOFIBROSIS PHASE
Clinical trials for POLYCYTHEMIA VERA, POST-POLYCYTHEMIC MYELOFIBROSIS PHASE explained in plain language.
Never miss a new study
Get alerted when new POLYCYTHEMIA VERA, POST-POLYCYTHEMIC MYELOFIBROSIS PHASE trials appear
Sign up with your email to follow new studies for POLYCYTHEMIA VERA, POST-POLYCYTHEMIC MYELOFIBROSIS PHASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail shows promise for Hard-to-Treat leukemia
Disease control OngoingThis early-phase trial tests a combination of three drugs—azacitidine, venetoclax, and pevonedistat—in adults newly diagnosed with a challenging form of acute myeloid leukemia (AML). The goal is to find the best dose and see if the combo can improve remission rates. About 40 part…
Matched conditions: POLYCYTHEMIA VERA, POST-POLYCYTHEMIC MYELOFIBROSIS PHASE
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Promising antibody drug takes on hard-to-treat bone marrow cancer
Disease control OngoingThis early study tests whether elotuzumab can help people with a specific type of myelofibrosis, a serious bone marrow disorder. The drug targets a protein on cancer cells to try to improve blood counts, shrink an enlarged spleen, and ease symptoms. The trial includes 15 adults w…
Matched conditions: POLYCYTHEMIA VERA, POST-POLYCYTHEMIC MYELOFIBROSIS PHASE
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC